Pathos: Funding, Investors & Team (Sep 2026)
Pathos stems from the idea that cancer is a range of rare diseases and can be defined by pathways that account for patient's pathophysiology. We license or collaborate on clinical-stage treatments to ensure effective drugs are created for patients with significant needs. Our patient selection methods are designed to speed up approval for better outcomes, aiming to translate real-world data into innovative therapies for those who need them most.
Pathos has raised $427M across 2 funding rounds on record, the most recent a Series D of $365M announced in May 2025.
That round is above the $5.7M median round size for Artificial Intelligence companies tracked on FundedIQ over the last two years.
Pathos Company Profile and Key Stats
Latest funding round on record: May 2025.
Pathos Funding Rounds
Pathos raised $62.0M in a Series C announced in Oct 2024.
7 months later, a Series D of $365M was announced in May 2025.
Pathos Founders and Leadership Team
Contact details for the Pathos team: 1 of 1 has an email address on file.
Start 14-day free trial →Pathos Funding Compared to Other Artificial Intelligence Startups
Pathos' latest round of $365M is above the median round in Artificial Intelligence. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pathos in Artificial Intelligence and New York
Companies Similar to Pathos
Cradlewise is an intelligent baby crib that learns from the baby's sleep patterns, spots the first signs of…
Capacity is an AI-powered helpdesk that automates support for customers and employees. Capacity connects…
AfterQuery is an artificial intelligence research and data platform focused on creating high-quality,…
The future of translation is conversational and Language I/O’s proprietary machine translation optimization…
Greptile is a platform driven by artificial intelligence that evaluates codebases and improves development…
Rhealth is a biotechnology company offering hospitals health management solutions utilizing advanced AI…
Socure is a predictive analytics platform for digital identity verification of consumers. Socure's predictive…
Instinct is an artificial intelligence startup developing AI technology.
Significant gives vehicle-mounted PC vision innovation that distinguishes visual deformities in network…
Cloverleaf AI exists to help you fill your pipeline with high-quality SLED leads. Tell us what you deliver,…
Emerald AI develops software and platforms that manage and coordinate energy use for artificial intelligence…
Pathos Funding FAQs
What does Pathos do?
Pathos stems from the idea that cancer is a range of rare diseases and can be defined by pathways that account for patient's pathophysiology. We license or collaborate on clinical-stage treatments to ensure effective drugs are created for patients with significant needs. Our patient selection methods are designed to speed up approval for better outcomes, aiming to translate real-world data into innovative therapies for those who need them most.
How much funding has Pathos raised?
Pathos has raised $427M across 2 rounds on record. The most recent is a Series D of $365M announced in May 2025.
When did Pathos last raise funding?
Pathos' most recent funding round on record is a Series D of $365M, announced in May 2025.
Who founded Pathos?
FundedIQ lists Ryan Fukushima (Founder) at Pathos.
Where is Pathos headquartered?
Pathos is based in New York, United States.
How many employees does Pathos have?
Pathos is in the 51-100 employee band.
How does Pathos' funding compare to other Artificial Intelligence startups?
Pathos' latest round of $365M is above the $5.7M median round size for Artificial Intelligence companies on FundedIQ across 7,234 tracked companies over the last two years.
About FundedIQ's Pathos Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pathos is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.